Myriad Genetics (MYGN) Cash & Equivalents (2009 - 2026)

Myriad Genetics has disclosed Cash & Equivalents across 18 years of filings, most recently posting $124.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 35.51% year-over-year to $124.4 million; the TTM figure through Mar 2026 stood at $124.4 million (up 35.51% YoY), while the FY2025 annual figure was $149.6 million, up 46.09% from the prior year.
• Cash & Equivalents slipped to $124.4 million in Q1 2026, from $149.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MYGN reached as high as $164.2 million in Q1 2022 and fell as low as $53.6 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $102.4 million (2024), against an average of $104.5 million.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 77.89% — and 2023, when it surged 132.16%.
• A 5-year view of Cash & Equivalents shows it stood at $56.9 million in 2022, then soared by 132.16% to $132.1 million in 2023, then fell by 22.48% to $102.4 million in 2024, then soared by 46.09% to $149.6 million in 2025, then decreased by 16.84% to $124.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $124.4 million, $149.6 million, and $145.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.